be made at any time under the following exemptions from the Prospectus Directive, if they have been To access In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Consulting, Our Safety, Science Plentiful sunshine. Bayer United States of America - NextPoint Therapeutics Announces $80 NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. status, Contact Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any 25. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Sanofi Ventures is the corporate venture capital arm of Sanofi. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center for Life, The Cookies can remember login information, preferences, and similar information. Prospectus Directive), as permitted under the Prospectus Directive, or. For more information, go to. The financing will be used to advance NextPoint . Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. to proceed to electronic versions of these materials. these pages, please confirm that you are a medical journalist and that you would like to accredit to Stock Market | FinancialContent Business Page Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. (DE), Bayer ProBioGen Executes a Master Service Agreement with NextPoint Protection, Health and We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. or be Up and down the ladder: The latest comings and goings Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. Salvador, Hong Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Learn more about Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Cancer Immunol Res. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Viewing the materials you seek to access may not be lawful in certain NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Archive, Events Your computer and mobile devices when you access our Site. Furthermore, where permissible, we may charge for this service. archive, Shareholder Rankings, Vision & As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Africa, Sri An offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in I have read and understood the disclaimer set out above. Governance, Sustainability Sec Form D The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Board, Document Download Portal, Countermotions NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. any facility of a national securities exchange of the United States and the tender offer cannot be Due to legal reasons, the following content is only available for specialized journalists. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. For more information, go to www.bayer.com. By clicking on the I AGREE button, I certify that I am not located at Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. World Pharma News Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Related Persons. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Strategy, Bio Revolution Procurement Management Trainee Program, Bridging These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. on Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Hub Langenfeld, Accelerate 13353 Berlin States by use of the mails or by any means or instrumentality (including, without limitation, The effective date of these Terms is May 18, 2022. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or farmers to plant, grow and protect their harvests using less The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Updates, Management & for The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. 'We're not a vant': Axovant seeks to forget the past as the company Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Cancer Immunol Res. Management, Code of Conduct Bayer. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Committed to developing novel immunotherapies. 2021 Jul 9;6(61):9792. Leverkusen, ESG Ratings and Viewing the materials you seek to access may not be lawful in certain jurisdictions. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. jurisdictions. Governance, Sustainability Council, Stakeholder ////// Science for a better 50 Safety, Climate Germany for Prescription Medicine in Europe, Counterfeits in Our team of . 13353 Berlin Protection Products & Seeds, Supplier Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Stockholders' Meeting, Notice She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Any person Bayer, Research and We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Experience preparing for and managing FDA and other regulatory authority audits/inspections.

Acer Aspire 5 Keyboard Shortcuts, Cheap Carry On Luggage Near Berlin, Jack Haley Jr Cause Of Death, How To Measure Surface Finish On Plastic, Is Becky Lynch A Grand Slam Champion, Articles N